Replimune Group Inc.(REPL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

REPL Replimune Group Inc.

盘前交易 07-02 08:43:30 EDT

11.22

+0.15

+1.36%

盘前11.25

+0.03+0.23%

08:18 EDT

最高11.70	最低11.04	成交量297.57万
今开11.10	昨收11.07	日振幅5.96%
总市值9.42亿	流通市值6.70亿	总股本8,395万
成交额3,366万	换手率4.98%	流通股本5,971万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"REPL","market":"US","secType":"STK","nameCN":"Replimune Group Inc.","latestPrice":11.22,"timestamp":1782936000000,"preClose":11.07,"halted":0,"volume":2975672,"hourTrading":{"tag":"盘前","latestPrice":11.2459,"preClose":11.22,"latestTime":"08:18 EDT","volume":1018,"amount":11454.628638,"timestamp":1782994723778,"change":0.0259,"changeRate":0.002308,"amplitude":0.030303},"delay":0,"changeRate":0.013550135501355046,"floatShares":59711800,"shares":83945161,"eps":-3.382838,"marketStatus":"盘前交易","change":0.15,"latestTime":"07-02 08:43:30 EDT","open":11.1,"high":11.7,"low":11.04,"amount":33662655.507656,"amplitude":0.059621,"askPrice":11.43,"askSize":24,"bidPrice":11.21,"bidSize":24,"shortable":3,"etf":0,"ttmEps":-3.382838,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782999000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1532059200000,"exchange":"NASDAQ","adjPreClose":11.22,"preHourTrading":{"tag":"盘前","latestPrice":11.2459,"preClose":11.22,"latestTime":"08:18 EDT","volume":1018,"amount":11454.628638,"timestamp":1782994723778,"change":0.0259,"changeRate":0.002308,"amplitude":0.030303},"postHourTrading":{"tag":"盘后","latestPrice":11.21,"preClose":11.22,"latestTime":"19:40 EDT","volume":17343,"amount":194630.5211,"timestamp":1782949226716,"change":-0.01,"changeRate":-0.000891,"amplitude":0.030303},"volumeRatio":0.6428155521418736,"impliedVol":1.6369,"impliedVolPercentile":0.768},"requestUrl":"/m/hq/s/REPL/wiki","defaultTab":"wiki","newsList":[{"id":"1198316202","title":"Replimune公布2026财年第四季度及全年业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1198316202","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198316202?lang=zh_cn&edition=full","pubTime":"2026-06-29 20:00","pubTimestamp":1782734429,"startTime":"0","endTime":"0","summary":"Replimune Group Inc. 已发布其2026财年第四季度及全年财务报告，同时向市场通报了公司最新的运营动态。此次披露涵盖了关键财务数据与战略发展近况，为投资者提供了评估公司业绩与未来前景的重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170634578","title":"摩根大通将Replimune Group评级上调至“增持”，目标价翻倍至17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170634578","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170634578?lang=zh_cn&edition=full","pubTime":"2026-06-26 23:30","pubTimestamp":1782487819,"startTime":"0","endTime":"0","summary":"摩根大通发布最新研究报告，将生物技术公司Replimune Group Inc.的股票评级从“中性”大幅上调至“增持”。与此同时，该行将其目标价从原先的8美元显著提升至17美元，涨幅超过一倍。\n此举反映了摩根大通对该公司未来发展前景的积极看法转变。目标价的大幅上调，通常意味着分析师认为公司基本面或市场环境出现了显著改善，其股价有较大的上行潜力。评级调整与目标价变动，是投资者评估股票价值与风险时关注的重要参考指标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199980725","title":"Replimune宣布FDA受理其Rp1生物制品许可申请重新提交，用于晚期黑色素瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1199980725","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199980725?lang=zh_cn&edition=full","pubTime":"2026-06-26 20:00","pubTimestamp":1782475247,"startTime":"0","endTime":"0","summary":"Replimune Group Inc. 宣布，美国食品药品监督管理局（FDA）已正式受理其针对候选疗法RP1用于治疗晚期黑色素瘤的生物制品许可申请（BLA）的重新提交。\n此次受理标志着该公司在推进这一溶瘤病毒免疫疗法上市进程中迈出了关键一步。FDA设定的处方药用户费用法案（PDUFA）目标审评日期为2024年12月25日。\n该BLA的提交主要基于关键的CERPASS临床试验数据，该研究评估了RP1与抗PD-1疗法利博利单抗联合使用，相较于单独使用利博利单抗，在晚期黑色素瘤患者中的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189204083","title":"Replimune Group：Rp1联合纳武利尤单抗在抗PD-1治疗失败的黑色素瘤患者中实现32.9个月中位总生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1189204083","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189204083?lang=zh_cn&edition=full","pubTime":"2026-05-30 20:11","pubTimestamp":1780143081,"startTime":"0","endTime":"0","summary":"Replimune Group Inc.公布其候选疗法Rp1联合纳武利尤单抗的最新数据，在对抗PD-1疗法已产生耐药性的晚期黑色素瘤患者群体中，展现出令人瞩目的长期生存获益，中位总生存期达到32.9个月。这一结果凸显了该联合疗法为这类难治性患者提供潜在新治疗选择的临床价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639067536","title":"美股异动 | 两次遭FDA拒绝后Replimune(REPL.US)皮肤癌药物迎转机 股价暴涨超77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639067536","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639067536?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:30","pubTimestamp":1780065021,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，Replimune股价暴涨，截至发稿，该股涨超77%，报8.27美元。今年4月，FDA第二次否决了Replimune针对晚期黑色素瘤的联合疗法，该方案结合了公司自研的免疫疗法与另一种抗癌药物。FDA此次转变态度，决定重新考虑Replimune的申请，外界普遍解读为，该机构在药物审评方面的强硬立场可能正在松动。截至周四收盘，Replimune股价今年已累计下跌52%。近期FDA连续拒绝多款药物申请，已引发业界普遍担忧。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","BK4139","REPL","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143933611","title":"Replimune有望与FDA达成协议，将重新提交晚期黑色素瘤疗法以寻求批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1143933611","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143933611?lang=zh_cn&edition=full","pubTime":"2026-05-29 19:34","pubTimestamp":1780054456,"startTime":"0","endTime":"0","summary":"生物技术公司Replimune Group Inc.预计将宣布与美国食品药品监督管理局（FDA）达成一项协议，为其晚期黑色素瘤治疗药物重新提交上市申请。\n根据报道，双方已就相关事宜进行了沟通，并有望在近期正式公布这一安排。此举旨在解决此前申请过程中可能存在的问题，并为该疗法的最终获批铺平道路。\nReplimune的这款疗法针对晚期黑色素瘤患者，属于其研发管线中的重要候选药物。与监管机构达成协议，通常意味着公司获得了明确的路径指引，以补充数据或调整方案，从而再次寻求监管批准。这一进展对于依赖该产品未来商业前景的Replimune而言，是一个积极的信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147501425","title":"FDA局长Marty Makary为机构对Replimune癌症药物决定辩护后，公司股价下跌5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1147501425","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147501425?lang=zh_cn&edition=full","pubTime":"2026-05-05 22:52","pubTimestamp":1777992722,"startTime":"0","endTime":"0","summary":"在FDA局长Marty Makary公开为监管机构对Replimune Group Inc.癌症药物的审评决定进行辩护后，该公司股价应声下跌5%。\n这一市场反应凸显了投资者对监管态度的敏感程度。Makary局长的表态被视为对Replimune药物前景的重要信号，直接影响了市场情绪。\n生物科技板块往往对监管动态表现出高度敏感性。此次股价波动再次印证了这一行业特性，同时也反映出市场对Replimune特定药物研发进展的持续关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188277711","title":"Replimune股价盘前暴跌58% 两款皮肤癌疗法未获FDA批准遭多家券商降级","url":"https://stock-news.laohu8.com/highlight/detail?id=1188277711","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188277711?lang=zh_cn&edition=full","pubTime":"2026-04-13 16:08","pubTimestamp":1776067703,"startTime":"0","endTime":"0","summary":"生物技术公司Replimune Group Inc. (REPL) 股价在盘前交易中重挫58%，创下历史最大单日跌幅。此次暴跌源于该公司针对晚期皮肤癌的两款核心疗法未能获得美国食品药品监督管理局（FDA）的批准许可。\n至少两家知名券商随后发布紧急报告，同步下调该股投资评级。分析师指出，监管审批的挫败不仅直接影响公司短期现金流，更对其肿瘤免疫疗法的商业化前景造成实质性打击。\n市场人士认为，此次FDA的否决决定可能迫使Replimune重新调整临床开发策略。受此影响，多只生物科技ETF持仓组合中出现连锁反应，板块情绪显著受挫。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106873747","title":"Replimune：基于FDA反馈启动Ignyte-3试验，满足加速批准所需的确证性研究要求","url":"https://stock-news.laohu8.com/highlight/detail?id=1106873747","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106873747?lang=zh_cn&edition=full","pubTime":"2026-04-11 05:06","pubTimestamp":1775855171,"startTime":"0","endTime":"0","summary":"生物技术公司Replimune Group Inc. (REPL) 宣布，根据美国食品药品监督管理局（FDA）的反馈，公司已正式启动Ignyte-3临床试验。此举旨在满足监管机构对加速批准路径的要求，即相关确证性研究必须正在进行中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186610525","title":"Replimune Group与FDA就RP1药物BLA数据集是否足以获批用于晚期癌症患者存在分歧","url":"https://stock-news.laohu8.com/highlight/detail?id=1186610525","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186610525?lang=zh_cn&edition=full","pubTime":"2026-04-11 05:05","pubTimestamp":1775855138,"startTime":"0","endTime":"0","summary":"生物制药公司Replimune Group Inc.与美国食品药品监督管理局（FDA）在关键药物RP1的上市申请数据充分性问题上产生意见分歧。该公司认为，当前提交的生物制品许可申请（BLA）数据集已具备足够证据支持该疗法用于晚期癌症患者，但监管机构对此持保留态度。这一争议直接关系到该创新疗法能否加速惠及亟待新治疗方案的患者群体。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110263267","title":"Replimune Group Inc. 宣布裁员，美国生产基地将大幅缩减运营规模","url":"https://stock-news.laohu8.com/highlight/detail?id=1110263267","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110263267?lang=zh_cn&edition=full","pubTime":"2026-04-11 05:05","pubTimestamp":1775855113,"startTime":"0","endTime":"0","summary":"在面临严峻的经营挑战下，生物制药公司Replimune Group Inc. 今日宣布了一项艰难的决定：公司将不得不进行裁员，并大幅缩减其在美国的生产运营规模。这一举措旨在优化资源配置，以应对当前复杂的市场环境。\n公司表示，此次运营调整实属无奈之举，是确保企业长期可持续发展的重要步骤。通过精简生产结构和人员队伍，Replimune Group Inc. 希望能够更加专注于核心研发领域，为未来的增长奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130606061","title":"FDA完全回应函：Replimune溶瘤病毒疗法有效性数据不足","url":"https://stock-news.laohu8.com/highlight/detail?id=1130606061","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130606061?lang=zh_cn&edition=full","pubTime":"2026-04-10 23:23","pubTimestamp":1775834592,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）在针对Replimune Group Inc.的完全回应函中指出，现有临床数据尚不足以证明其溶瘤病毒疗法vusolimogene oderparepvec具有显著有效性。监管机构认为，当前提交的证据未能达到\"实质性有效证明\"的审评标准，要求企业补充更多临床数据支持该疗法的疗效结论。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605181514","title":"Replimune Group, Inc.盘中异动 急速上涨5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605181514","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605181514?lang=zh_cn&edition=full","pubTime":"2026-01-22 23:17","pubTimestamp":1769095068,"startTime":"0","endTime":"0","summary":"北京时间2026年01月22日23时17分，Replimune Group, Inc.股票出现波动，股价急速拉升5.37%。Replimune Group, Inc.股票所在的生物技术行业中，整体涨幅为1.05%。其相关个股中，60 Degrees Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Cabaletta Bio, Inc.涨幅较大，60 Degrees Pharmaceuticals, Inc.、Oragenics Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为11352.19%、367.35%、284.48%，振幅较大的相关个股有60 Degrees Pharmaceuticals, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为131.00%、69.40%、36.70%。Replimune Group, Inc.公司简介：Replimune Group Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122231748a6a12932&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122231748a6a12932&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516668787","title":"Replimune Group, Inc.盘中异动 急速跳水5.13%报12.03美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516668787","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516668787?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:10","pubTimestamp":1741032617,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时10分，Replimune Group, Inc.股票出现异动，股价急速下跌5.13%。截至发稿，该股报12.03美元/股，成交量30.7721万股，换手率0.40%，振幅8.83%。Replimune Group, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Celularity Inc C/Wts 16/07/2026 涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4590.81%、212.56%、182.81%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Replimune Group, Inc.公司简介：Replimune Group Inc是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041017abe69136&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041017abe69136&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516706583","title":"Replimune Group, Inc.盘中异动 大幅下跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516706583","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516706583?lang=zh_cn&edition=full","pubTime":"2025-03-01 01:46","pubTimestamp":1740764777,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日01时46分，Replimune Group, Inc.股票出现波动，股价大幅下挫5.03%。Replimune Group, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Camp4 Therapeutics Corporation涨幅较大，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为3119.37%、511.46%、374.69%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 ，振幅分别为57.80%、49.50%、48.19%。Replimune Group, Inc.公司简介：Replimune Group Inc是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301014617a25830af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301014617a25830af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514865334","title":"Replimune Group, Inc.盘中异动 下午盘股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514865334","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514865334?lang=zh_cn&edition=full","pubTime":"2025-02-28 03:41","pubTimestamp":1740685271,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日03时41分，Replimune Group, Inc.股票出现波动，股价急速下跌5.02%。Replimune Group, Inc.股票所在的生物技术行业中，整体跌幅为0.23%。其相关个股中，Pepgen Inc.、Alpha Tau Medical Ltd C/Wts 、Ibio, Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Vincerx Pharma, Inc.较为活跃，换手率分别为1907.10%、331.35%、184.86%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pepgen Inc.、Pds Biotechnology Corporation，振幅分别为86.14%、67.32%、55.84%。Replimune Group, Inc.公司简介：Replimune Group Inc是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228034111abdfb2d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228034111abdfb2d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514857702","title":"小摩：维持Replimune Group(REPL.US)评级，由增持调整至增持评级, 目标价由16.00美元调整至18.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514857702","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514857702?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:23","pubTimestamp":1740587009,"startTime":"0","endTime":"0","summary":"小摩：维持Replimune Group(REPL.US)评级，由增持调整至增持评级, 目标价由16.00美元调整至18.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27002348413726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513196202","title":"Replimune Group, Inc.盘中异动 急速下挫5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513196202","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513196202?lang=zh_cn&edition=full","pubTime":"2025-02-22 02:52","pubTimestamp":1740163926,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日02时52分，Replimune Group, Inc.股票出现波动，股价大幅下跌5.17%。Replimune Group, Inc.股票所在的生物技术行业中，整体涨幅为0.27%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Revolution Medicines Inc C/Wts 17/12/2026 、Invivyd, Inc.涨幅较大，Aditxt, Inc.、Nkgen Biotech, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为292.25%、247.52%、136.45%，振幅较大的相关个股有Osr Holdings, Inc.、Invivyd, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为76.52%、70.25%、61.26%。Replimune Group, Inc.公司简介：Replimune Group Inc是一家临床阶段生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222025206962bb439&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222025206962bb439&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511540882","title":"HC Wainwright & Co.：维持Replimune Group(REPL.US)评级，由买入调整至买入评级, 目标价由21.00美元调整至22.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511540882","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511540882?lang=zh_cn&edition=full","pubTime":"2025-02-13 21:24","pubTimestamp":1739453047,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Replimune Group(REPL.US)评级，由买入调整至买入评级, 目标价由21.00美元调整至22.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/13212448148730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510372470","title":"Replimune Group(REPL.US)：2025年Q3财报实现营收0美元，前值为0美元；每股收益为-0.79美元，前值为-0.77美元，预期值为-0.75美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510372470","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510372470?lang=zh_cn&edition=full","pubTime":"2025-02-12 21:54","pubTimestamp":1739368470,"startTime":"0","endTime":"0","summary":"Replimune Group(REPL.US)：2025年Q3财报实现营收0美元，前值为0美元；每股收益为-0.79美元，前值为-0.77美元，预期值为-0.75美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/12215448121698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["REPL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.replimune.com","stockEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.2467},{"period":"3month","weight":0.3341},{"period":"6month","weight":0.2607},{"period":"1year","weight":0.2262},{"period":"ytd","weight":0.1543}],"compareEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.0168},{"period":"3month","weight":0.1371},{"period":"6month","weight":0.0916},{"period":"1year","weight":0.2074},{"period":"ytd","weight":0.0936}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Replimune Group, Inc.于2015年在特拉华州注册成立。该公司是一家临床阶段的生物技术公司，致力于应用他们在溶瘤免疫治疗领域的领先专业技术，改变癌症患者的生活。使用该公司专有的Immulytic平台来设计和开发旨在最大限度激活免疫系统对抗癌症的候选产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":-0.013766},{"month":2,"riseRate":0.375,"avgChangeRate":-0.050762},{"month":3,"riseRate":0.25,"avgChangeRate":-0.088086},{"month":4,"riseRate":0.5,"avgChangeRate":0.020849},{"month":5,"riseRate":0.5,"avgChangeRate":0.255044},{"month":6,"riseRate":0.875,"avgChangeRate":0.229422},{"month":7,"riseRate":0.375,"avgChangeRate":-0.075688},{"month":8,"riseRate":0.375,"avgChangeRate":0.023484},{"month":9,"riseRate":0.25,"avgChangeRate":-0.055352},{"month":10,"riseRate":0.625,"avgChangeRate":0.268092},{"month":11,"riseRate":0.625,"avgChangeRate":0.036282},{"month":12,"riseRate":0.25,"avgChangeRate":-0.087028}],"exchange":"NASDAQ","name":"Replimune Group Inc.","nameEN":"Replimune Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Replimune Group Inc.(REPL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Replimune Group Inc.(REPL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Replimune Group Inc.,REPL,Replimune Group Inc.股票,Replimune Group Inc.股票老虎,Replimune Group Inc.股票老虎国际,Replimune Group Inc.行情,Replimune Group Inc.股票行情,Replimune Group Inc.股价,Replimune Group Inc.股市,Replimune Group Inc.股票价格,Replimune Group Inc.股票交易,Replimune Group Inc.股票购买,Replimune Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Replimune Group Inc.(REPL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Replimune Group Inc.(REPL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}